Koss-Olinger Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-370
| Closed | -$235K | – | 326 |
|
|
2025
Q1 | $235K | Buy |
+370
| New | +$235K | 0.02% | 278 |
|
|
2024
Q4 | – | Sell |
-353
| Closed | -$371K | – | 267 |
|
|
2024
Q3 | $371K | Buy |
353
+24
| +7% | +$25.2K | 0.03% | 198 |
|
|
2024
Q2 | $346K | Buy |
+329
| New | +$346K | 0.03% | 193 |
|
|
2024
Q1 | – | Sell |
-320
| Closed | -$281K | – | 238 |
|
|
2023
Q4 | $281K | Hold |
320
| – | – | 0.03% | 244 |
|
|
2023
Q3 | $263K | Hold |
320
| – | – | 0.04% | 215 |
|
|
2023
Q2 | $230K | Hold |
320
| – | – | 0.03% | 229 |
|
|
2023
Q1 | $263K | Buy |
320
+26
| +9% | +$21.4K | 0.03% | 192 |
|
|
2022
Q4 | $212K | Sell |
294
-125
| -30% | -$90.1K | 0.03% | 202 |
|
|
2022
Q3 | $289K | Buy |
419
+56
| +15% | +$38.6K | 0.05% | 158 |
|
|
2022
Q2 | $215K | Buy |
363
+13
| +4% | +$7.7K | 0.04% | 159 |
|
|
2022
Q1 | $244K | Sell |
350
-135
| -28% | -$94.1K | 0.04% | 162 |
|
|
2021
Q4 | $306K | Buy |
485
+18
| +4% | +$11.4K | 0.05% | 154 |
|
|
2021
Q3 | $283K | Buy |
+467
| New | +$283K | 0.05% | 181 |
|